Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants

15 juli 2026 uppdaterad av: Novartis Pharmaceuticals

A Prospective Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants With Symptomatic Cryptosporidiosis in Endemic Countries

This study aims to characterize the pediatric cryptosporidiosis disease profile with respect to clinical presentation.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Observationell

Inskrivning (Beräknad)

30

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Novartis Pharmaceuticals

Studieorter

    • Nyanza
      • Kisumu, Nyanza, Kenya, 40100
        • Rekrytering
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia, 56000
        • Rekrytering
        • Novartis Investigative Site
    • Pahang
      • Kuantan, Pahang, Malaysia, 25200
        • Rekrytering
        • Novartis Investigative Site
      • Lusaka, Zambia, 10101
        • Rekrytering
        • Novartis Investigative Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Pediatric participants presenting with diarrhea and testing positive for Cryptosporidium by QuikChek™ and microscopy.

Beskrivning

Inclusion criteria:

  • Age 6 months to 59 months with diarrhea according to the World Health Organization (WHO) criteria (≥3 loose stools daily for at least 2 days)
  • QuikChek™ and Stool microscopy positive for Cryptosporidium at screening
  • Acute (<7 days), prolonged (lasting 7-13 days), persistent (lasting 14-28 days) or chronic (lasting >28 days) diarrheal illness (≥3 loose stools daily, as defined by WHO) at screening
  • Normal nutritional status, mildly-to-moderately acutely malnourished, or severely acutely malnourished according to WHO definitions (number of participants with severe acute malnutrition will be capped) at screening
  • Parent or primary caregiver is willing to provide informed consent and to comply with study procedures, including provision of whole stool samples at the scheduled time points and willing to be followed up to 21 days

Exclusion criteria:

  • Bloody diarrhea, defined as diarrhea with visible blood in stool as observed by the study team member performing the screening or reported by parent/primary caregiver
  • Other morbidity requiring emergency medical care in an intensive care setting at the time of screening
  • Coincident non-enteric infection including upper or lower respiratory infection at screening
  • Any participant whose parent or primary caregiver is unwilling or unable to cooperate with study procedures, in the investigator's opinion
  • If the parent/primary caregiver managing care of the patient has travel plans out of the study area that would preclude clinic or in-home study visits during the expected study follow-up period

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Cryptosporidiosis Cohort
Pediatric participants with diarrhea due to Cryptosporidium infection.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number and Percentage of Participants by Chronicity of Diarrhea
Tidsram: Baseline

Diarrhea chronicity categories:

  • Acute (<7 days)
  • Prolonged (7-13 days)
  • Persistent (14-28 days)
  • Chronic (>28 days)
Baseline
Number and Percentage of Participants by Severity of Dehydration
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21

Dehydration severity categories:

  • None
  • Some
  • Severe
Baseline, Days 3, 7, 14 and up to Day 21
Time to Resolution of Diarrhea and Dehydration
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Baseline, Days 3, 7, 14 and up to Day 21

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Association of Diarrheal Chronicity With Age
Tidsram: Baseline
Association of diarrheal chronicity with age will be assessed using the Kruskal-Wallis test.
Baseline
Association of Diarrheal Chronicity With Height
Tidsram: Baseline
Association of diarrheal chronicity with height will be assessed using the Kruskal-Wallis test.
Baseline
Association of Diarrheal Chronicity With Weight
Tidsram: Baseline
Association of diarrheal chronicity with weight will be assessed using the Kruskal-Wallis test.
Baseline
Association of Diarrheal Chronicity With Sex
Tidsram: Baseline
Association of diarrheal chronicity with sex will be assessed using the Fisher exact test.
Baseline
Association of Diarrheal Chronicity With HIV Status
Tidsram: Baseline
Association of diarrheal chronicity with HIV status will be assessed using the Fisher exact test.
Baseline
Association of Diarrheal Chronicity With Malnutrition
Tidsram: Baseline
Association of diarrheal chronicity with malnutrition will be assessed using the Fisher exact test.
Baseline
Association of Diarrheal Chronicity With Growth Faltering
Tidsram: Baseline
Association of diarrheal chronicity with growth faltering will be assessed using the Fisher exact test.
Baseline
Association of Diarrheal Chronicity With Early Weaning
Tidsram: Baseline
Association of diarrheal chronicity with early weaning will be assessed using the Fisher exact test.
Baseline
Association of Diarrheal Chronicity With Non-Exclusive Breast Feeding
Tidsram: Baseline
Association of diarrheal chronicity with early non-exclusive breast feeding will be assessed using the Fisher exact test.
Baseline
Association of Dehydration Severity With Age
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with age will be assessed using the Kruskal-Wallis test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Height
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with height will be assessed using the Kruskal-Wallis test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Weight
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with weight will be assessed using the Kruskal-Wallis test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Sex
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with sex will be assessed using the Fisher exact test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With HIV Status
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with HIV status will be assessed using the Fisher exact test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Malnutrition
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with malnutrition will be assessed using the Fisher exact test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Growth Faltering
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with growth faltering will be assessed using the Fisher exact test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Early Weaning
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with early weaning will be assessed using the Fisher exact test.
Baseline, Days 3, 7, 14 and up to Day 21
Association of Dehydration Severity With Non-Exclusive Breast Feeding
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Association of dehydration severity with early non-exclusive breast feeding will be assessed using the Fisher exact test.
Baseline, Days 3, 7, 14 and up to Day 21
Number of Oocysts
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Baseline, Days 3, 7, 14 and up to Day 21
Proportion of Participants Shedding Oocysts
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Baseline, Days 3, 7, 14 and up to Day 21
Number of Participants by Parasite Presence Measured by Microscopy and the QuikChek™ Cryptosporidium Rapid Diagnostic Test (RDT)
Tidsram: Baseline, Days 3, 7, 14 and up to Day 21
Baseline, Days 3, 7, 14 and up to Day 21
Number of Participants Screened for Each Site by Time of Year
Tidsram: Baseline
Number of participants screened (i.e., present with diarrheal illness) for each site by time of year (i.e., per season).
Baseline
Number of Participants Enrolled for Each Site by Time of Year
Tidsram: Baseline
Number of participants enrolled (i.e., Cryptosporidium positive) for each site by time of year (i.e., per season).
Baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 januari 2026

Primärt slutförande (Beräknad)

19 maj 2027

Avslutad studie (Beräknad)

19 maj 2027

Studieregistreringsdatum

Först inskickad

29 juni 2026

Först inskickad som uppfyllde QC-kriterierna

15 juli 2026

Första postat (Faktisk)

21 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera